Computational Drug Repurposing for Endometriosis Using Single-Cell RNA Sequencing — Patent Specification

This patent specification describes a computational drug-repurposing workflow for endometriosis using single-cell RNA sequencing, applying a standardized scRNA-seq pipeline that includes scVI batch correction, Leiden clustering, Wilcoxon differential expression, and drug candidate screening against ChEMBL. Using the GSE179640 dataset (47,957 endometrial biopsy cells across 32 samples), the approach identified 500 significant differentially expressed genes and scored 20,510 drug candidates, then confirmed 20,117 novel candidates via PubChem, with top-scoring examples including CHEMBL5653589, LESTAURTINIB, and CHEMBL3752910. The specification does not provide experimental validation of drug efficacy beyond the computational gene-expression–based screening. This paper is centrally about endometriosis — it proposes a scRNA-seq–driven computational drug repurposing method for identifying candidate drugs.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works